Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population by Wang, Lihong et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Association of CTLA-4 gene polymorphisms with sporadic breast 
cancer in Chinese Han population
Lihong Wang†1, Dalin Li†2, Zhenkun Fu1, Heng Li1, Wei Jiang3 and 
Dianjun Li*1
Address: 1Department of Immunology, Harbin Medical University, Harbin 150081, China, 2Department of Surgery, the Third Affiliated Hospital 
of Harbin Medical University, Harbin 150081, China and 3Department of Bioinformatics, Harbin Medical University, Harbin 150081, China
Email: Lihong Wang - jiangwlh@gmail.com; Dalin Li - lidalin1975@163.com; Zhenkun Fu - zhenkun_fu@yahoo.com.cn; 
Heng Li - 0213liheng@sina.com; Wei Jiang - jiangweilh@gmail.com; Dianjun Li* - dianjunli@163.com
* Corresponding author    †Equal contributors
Abstract
Background: The host immunogenetic background plays an important role in the development
of breast cancer. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a molecule expressed
predominantly on activated T cells and is important during the down-regulation of T-cell activation.
To evaluate the potential influences of CTLA-4 gene polymorphisms on breast cancer risk, a case-
control study was conducted in Han women of Northeast China.
Methods: We genotyped CTLA-4 variants (-1661 G/A, -658 T/C, -318 T/C, +49 G/A and CT60 G/
A) to tag all common haplotypes (≥ 1% frequency) in 117 Chinese breast cancer cases and 148 age/
sex matched healthy individuals. Genotypes were determined by the polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method. Data was analyzed using the Chi-
square test and Haploview software.
Results: The frequency of CTLA-4 -1661G allele, -318T allele and CT60G allele carriers was
significantly higher in patients than in controls (P = 0.0057, OR 1.91, 95% CI 1.21–3.02; P = 0.0031,
OR 2.39, 95% CI 1.34–4.27; P = 0.023, OR 1.52, 95% CI 1.06–2.17, respectively). The -658T allele
carrier frequency was significantly lower than in controls (P = 0.0000082, OR 0.17, 95% CI 0.08–
0.37), whereas the +49A allele was significantly associated with tumor size in patients (P = 0.0033).
Two common CTLA-4 haplotypes, ATCGA and ATCAG, were higher in healthy controls than
patients (P  = 0.0026, OR 0.17, 95% CI 0.05–0.54; P  = 0.034, OR 0.12, 95% CI 0.02–0.92,
respectively). A strong association was observed between tumor size and the ACCAA, ACCAG
and ACCGA haplotypes (P = 0.0032, P = 0.0000031 and P = 0.017).
Conclusion: These results suggest that polymorphisms of the CTLA-4 gene may modify individual
susceptibility to and progression of breast cancer in Chinese Han women.
Background
Breast cancer is the most common malignancy in women
worldwide and its rate is increasing in both developed and
developing countries. The etiology of breast cancer is
complicated and not completely known, but recent stud-
ies have focused on the role of the immune system. Dur-
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ing the development of breast cancer, innate and adaptive
responses are carefully orchestrated through soluble and
membrane-bound regulators, resulting in the deployment
of the most suitable effectors for controlling the growth of
tumor. However, the biological importance of these
responses is not fully understood [1]. The most significant
anti-tumor response is cell-mediated and involves T lym-
phocytes and natural killer (NK) cells. Thus, the variants
of those genes that regulate the activation and prolifera-
tion of T lymphocytes and NK cells may affect the risk of
breast cancer.
Cytotoxic T-lymphocyte antigen-4 (CTLA-4), encoded by
a gene on chromosome 2q33, is a receptor expressed by
activated T lymphocytes. It interacts with the B-7 cell sur-
face molecule on antigen-presenting cells and inhibits T
cell activation and clonal expansion [2,3]. CTLA-4 block-
ade leads to enhancement of the immune response [4],
rejection of tumors [5], or even cures mice of tumors
when used in combination with tumor vaccines [6]. The
CTLA-4 gene consists of four exons and has been shown
to be an important candidate gene for T cell-mediated dis-
eases. More than 100 single-nucleotide polymorphisms
(SNPs) have been identified in the CTLA-4 gene region
[7]. Several important polymorphic sites have been
reported in the entire region of the CTLA-4 gene. Among
these variants, only A/G dimorphism at position +49 in
exon 1 causes an amino acid exchange (threonine to
alanine) in the peptide leader sequence of the CTLA-4
protein. Significantly increased expression of CTLA-4
mRNA and protein have been shown in individuals carry-
ing thymine at position -318 of the CTLA-4 promoter and
those homozygous for adenine at position 49 in exon 1
[8]. Ueda et al. reported that the G allele at the CT60 posi-
tion was associated with a 50% decrease in the soluble
CTLA-4 isoform [7]. Previous studies have extensively
examined the association of polymorphisms within
CTLA-4 with autoimmune diseases including Graves' dis-
ease, type I diabetes, systemic lupus erythematosus, and
Hashimoto's thyroiditis [7,9-11], as well as malignancy
susceptibility [12-15]. Some reports imply that the distri-
bution of certain alleles of the CTLA-4 gene in cancer is
contrary to autoimmune diseases: that is, those alleles that
confer susceptibility to autoimmunity are sparse in
patients with cancer or associated with good prognosis of
the cancer. A recent report in an Iranian population
showed that there was an association of an AA genotype at
+49A/G with susceptibility to breast cancer and no signif-
icant differences in the promoter region (-1661 A/G and -
318 C/T) of the CTLA-4 gene polymorphisms between
patients and healthy controls [12,13]. To evaluate
whether these polymorphisms of the CTLA-4 gene were
likely to be of importance in Chinese breast cancer, we
typed patients and controls for five of these important
SNPs in the Chinese Han population of Northeast China.
The five polymorphic sites of the CTLA-4 gene included
three in the promoter region (-1661 G/A, -658 T/C, -318
T/C), one in exon 1 (+49 G/A) and one in 3'-UTR (CT60
G/A).
Methods
Subjects
The study group consisted of a total of 117 Chinese
women with breast cancer, ranging in age from 30 to 73
years (mean age at diagnosis 48.7 ± 9.5 years). These
patients came from the Department of Abdominal Sur-
gery (The Third Affiliated Hospital of Harbin Medical
University). Breast cancer was diagnosed from surgical
and pathological symptoms. The patients' pathological
and clinical information were obtained from their medi-
cal files (Table 1). The control group came from healthy
blood donors consisting of 148 unrelated age (mean age
at sampling 46.3 ± 17.0 years) matched women who were
randomly selected from community volunteers in the
same district, without a history of personal and familial
malignancy and autoimmune disorders. Both patients
and healthy controls originated from the Heilongjiang
Province of China between September 2005 and June
2006. Samples were obtained from subjects after they had
provided written informed consent.
DNA extraction and genotyping
Genomic DNA was extracted from 5 ml frozen whole
blood using the DNA Extraction Kit (Qiagen, Germany)
according to the manufacturer's protocol. A polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) assay was used to detect dimorphism of -
1661 G/A, -658 T/C, -318 T/C, +49 G/A and CT60 G/A.
The polymorphic region was amplified by PCR with a T-
Gradient Thermoblock PCR System iometra, Germany) in
a 25 µl reaction solution containing 0.3 µg genomic DNA,
Table 1: Clinicopathologic features of breast cancer patients (n = 
117)
Feature Cases, no. (%)
Tumor type
IDC 111 (94.9)
MC 4 (3.4)
Other 2 (1.7)
Tumor size (cm)
TZ≤2 39 (33.3)
2<TZ≤5 62 (53.0)
TZ>5 13 (11.1)
Unknown 3 (2.6)
LN involvement
Positive 60 (51.3)
Negative 57 (48.7)
Abbreviations: IDC, infiltrative ductal carcinoma; MC, medullary 
carcinoma; LN, lymph node; TZ, tumor size.BMC Cancer 2007, 7:173 http://www.biomedcentral.com/1471-2407/7/173
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1× PCR buffer, 0.3 mM MgCl2, 0.2 mM dNTPs, 2 U Taq
DNA polymerase (Takara, Japan) and 0.1 µmol of each
primer (Shenggong, China). SNPs were selected to tag all
common (≥ 1% population frequency) CTLA-4  haplo-
types. Genotyping primers and PCR programs are shown
in Table 2. PCR products were digested overnight with
restriction enzymes (NEB, UK) according to the manufac-
turer's protocol and analyzed by 2% agarose gel electro-
phoresis. Restriction enzymes and the length of digested
fragments are shown in Table 3. This methodology was
robust with a 97.8% genotype success rate [16].
Statistical analysis
We tested for Hardy-Weinberg equilibrium (HWE)
among cases and controls separately. SNPs were excluded
from the analysis if they were out of HWE (P < 0.05), had
a minor allele frequency of less than 5%, or had more
than 25% missing data. The allele and genotype frequen-
cies were obtained by direct counting. Statistical signifi-
cance was defined as P < 0.05. We used Haploview 3.2
software to reconstruct haplotypes and estimate haplo-
type frequencies in the unrelated cases and controls. In
order to obtain a measure of significance corrected for
multiple testing bias we ran 10,000 permutations to com-
pute  P-values using the Haploview program. Compari-
sons of the distributions of the allele, genotype and
haplotype frequencies were performed using the chi-
square test. The relative risk associated with rare alleles
was estimated as an odds ratio (OR) with a 95% confi-
dence interval (CI).
Table 3: Restriction enzymes and length of digested fragments
-1661G/A -658T/C -318T/C +49G/A CT60G/A
Enzyme Mse I Aci I Mse I Bbv I HpyCH4 IV
Length of digested A: 347+139 C: 254+112 T: 130+96+21 G: 255+56 G: 107+71
fragments (bp) G: 486 T: 366 C: 226+21 A: 311 A: 178
Table 2: Primers and PCR programs for CTLA-4 PCR-RFLP genotyping
Reference SNP ID Gene/SNP primer Sequence PCR program
rs4553808 CTLA-4 -1661G/A F 5'-
CTAAGAGCATCCGCTTGCAC
CT-3'
94°C 5 min; 30 cycles, 94°C 15s,
CTLA-4 -1661G/A R 5'-
TTGGTGTGATGCACAGAAGC
CTTT-3'
58°C 5s, 72°C 45s; 72°C 7 min
rs11571317 CTLA-4 -658T/C F 5'-
ATCATTGGTCCTGTCTACAGC
-3'
94°C 5 min; 35 cycles, 94°C 30s,
CTLA-4 -658T/C R 5'-
CTTCTAATGGTCCCTTGACAG
-3'
55.5°C 10s, 72°C 30s; 72°C 5 min
rs5742909 CTLA-4 -318T/C F 5'-
AAATGAATTGGACTGGATGG
T-3'
94°C 4 min; 30 cycles, 94 °C 30s,
CTLA-4 -318T/C R 5'-
TTACGAGAAAGGAAGCCGTG-
3'
55.6°C 5s, 72°C 30s; 72°C 4 min
rs231775 CTLA-4 +49G/A F 5'-
AGTCTCACTCACCTTTGCAG-
3'
94°C 4 min; 30 cycles, 94°C 30s,
CTLA-4 +49G/A R 5'-
GCTCTACCTCTTGAAGACCT-
3'
56.4°C 10s, 72°C 30s; 72°C 4 min
rs3087243 CTLA-4 CT60G/A F 5'-
GAGGTGAAGAACCTGTGTGT
TAAA-3'
94°C 5 min; 30 cycles, 94°C 30s,
CTLA-4 CT60G/A R 5'-
ATAATGCTTCATGAGTCAGCT
T-3'
55.6°C 30s, 72°C 30s; 72°C 5 minBMC Cancer 2007, 7:173 http://www.biomedcentral.com/1471-2407/7/173
Page 4 of 7
(page number not for citation purposes)
Results
Genotype and allele frequencies
The genotype and allele frequencies of the CTLA-4 gene
polymorphisms in breast cancer patients and healthy con-
trols are shown in Tables 4 and 5. All of the five SNPs gen-
otyped were in HWE (P > 0.05) in our case and control
cohort. The minor allele frequencies were more than 5%
and all of the missing data were less than 25%. When the
genotype frequencies were compared between cases and
controls, -1661, -658 and -318 SNPs showed statistically
significant association (Details in Table 4). The CTLA-4 -
1661 AA genotype and -318 CC genotype frequencies
were lower in patients than in controls (P = 0.0022, OR
0.44, 95% CI 0.26–0.74; P = 0.0018, OR 0.37, 95% CI
0.20–0.69). The CTLA-4 -1661G allele, -318T allele and
CT60G allele carrier frequencies were significantly higher
in patients than in controls (P = 0.0057, OR 1.91, 95% CI
1.21–3.02; P = 0.0031, OR 2.39, 95% CI 1.34–4.27; P =
0.023, OR 1.52, 95% CI 1.06–2.17, respectively). In con-
trast, the -658 CC genotype frequency was significantly
higher (P = 0.0000027, OR 6.92, 95% CI 3.08–15.52)
(Table 4) and the T allele carrier frequency was signifi-
cantly lower in patients than in controls (P = 0.0000082,
OR 0.17, 95% CI 0.08–0.37) (Table 5). After highly con-
servative correction for multiple testing, significant associ-
ation was only observed for the -1661G, -658T and -318T
alleles (P = 0.031, 0.00010 and 0.017, respectively). Sta-
tistical analysis revealed no significant differences in the
genotype and allele frequencies in +49 G/A between
patients and healthy controls. Analysis of association
between genotypes and predictive factors of breast cancer
revealed no association between genotypes at these five
SNP sites and lymph node metastasis. Tumor size was sig-
nificantly different between carriers of the AA (P = 0.026)
and GG (P = 0.0018) genotypes at position +49 G/A in
comparison to other genotypes. In addition, we found a
significant association between the +49A allele and tumor
size (P = 0.0033).
Haplotypes analysis
Haplotypes with frequencies ≥ 1% are shown in Table 6.
The most frequent haplotypes observed in patients and
controls were haplotype ACCAG (-1661A, -658C, -318C,
+49A, CT60G) (25.5%) and ACCGA (27.1%). However,
statistical analysis did not reveal significant differences in
the frequencies of these two haplotypes between patients
and healthy controls. The frequencies of haplotypes,
ATCGA and ATCAG, were significantly lower in patients
compared with healthy controls (P  = 0.0026 and P  =
0.034, respectively). However, after the P-value was cor-
rected for multiple testing using the permutation option
available in Haploview 3.2 software, a significant associa-
tion was only found for haplotype ATCGA (P = 0.012, OR
0.17, 95% CI 0.05–0.54).
Association with tumor prognostic or predictive factors
was also observed with certain haplotypes. Although there
was no association between haplotypes and lymph node
metastasis in patients, we found strong association of
tumor size with the ACCAA, ACCAG and ACCGA haplo-
types (P = 0.0032, P = 0.0000031 and P = 0.017, respec-
tively).
Discussion
The determination of genetic polymorphisms is a new
means to study the etiology of polygenetic disorders with
Table 4: Genotype frequencies of CTLA-4 polymorphisms in breast cancer patients and healthy controls
Genotype Frequency, no. (%) P-value Odds ratio (95% CI)
Patients (n = 117) Controls (n = 148)
-1661, G/A# AA 62 (56.9) 111 (75.0) 0.0022 0.44 (0.26–0.74)
AG 45 (41.3) 35 (23.7) 0.0025 2.27 (1.33–3.87)
GG 2 (1.8) 2 (1.4) 0.76
-658, T/C† CC 109 (94.8) 105 (72.4) 0.0000027 6.92 (3.08–15.52)
TC 6 (5.2) 40 (27.6) 0.0000027 0.14 (0.06–0.32)
TT 0 0
-318, T/C CC 84 (71.8) 129 (87.2) 0.0018 0.37 (0.20–0.69)
TC 33 (28.2) 19 (12.8) 0.0018 2.67 (1.44–4.93)
TT 0 0
+49, G/A AA 48 (41.0) 55 (37.2) 0.52
AG 59 (50.4) 70 (47.3) 0.61
GG 10 (8.6) 23 (15.5) 0.090
CT60, G/A AA 46 (39.3) 74 (50.0) 0.080
AG 47 (40.2) 56 (37.8) 0.70
GG 24 (20.5) 18 (12.2) 0.060
# patients (n = 109), missing (n = 8); controls (n = 148), missing (n = 0)
† patients (n = 115), missing (n = 2); controls (n = 145), missing (n = 3)BMC Cancer 2007, 7:173 http://www.biomedcentral.com/1471-2407/7/173
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complex inheritance patterns, such as cancer, diabetes and
hypertension [17]. CTLA-4 exerts distinct independent
effects during different phases of T cell responses, includ-
ing setting the threshold for T cell activation, suppression
of T cell proliferation, and induction of apoptosis in acti-
vated T cells [18]. It may even contribute directly to the
regulation of B cell responses, since B cells express CTLA-
4 after cell-cell contact with activated T cells [19]. Poly-
morphisms in the CTLA-4 gene have been tested for asso-
ciation with breast cancer in an Iranian population
[12,13]. In the case-control study described here, we
investigated the association between five putatively func-
tional polymorphisms (-1661 G/A, -658 T/C, -318 T/C,
+49 G/A and CT60 G/A) of the CTLA-4 gene and the risk
of sporadic breast cancer in Chinese Han women.
A promoter region is the transcription factor binding site
and regulates the level of expression of the gene [20]. This
was the first study indicating that in the CTLA-4 promoter
-658 CC genotype may increase breast cancer risk and -
658T allele has a protective role in breast cancer. We also
found that -1661 AA genotype and -318 CC genotype fre-
quencies were lower in patients than in controls. The -
1661G allele and -318T allele carrier frequencies were sig-
nificantly higher in patients than in controls. These results
suggest that these alleles might have an association with
breast cancer risk in Chinese Han women. In contrast,
there were no significant differences in genotype, allele, or
haplotype frequencies in -1661 A/G and -318 C/T loci
between patients and healthy controls in the Iranian pop-
ulation [13]. Some reports have suggested that the -318T
allele may play a protective role in autoimmune disease
[8,9]. The presence of the -318T allele may contribute to
Table 6: CTLA-4 haplotype frequencies in breast cancer patients and healthy controls
CTLA-4 haplotype Freq. Breast 
cancer (n = 
117)
Healthy 
controls (n 
= 148)
P-value Odds ratio 
(95% CI)
-1661 -658 -318 +49 CT60
A C C G A 0.25 22.1% 27.1% 0.19
A C C A G 0.22 25.5% 19.3% 0.089
A C C A A 0.20 16.5% 22.5% 0.085
G C T A A 0.062 8.1% 4.6% 0.081
A C C G G 0.058 8.0% 4.1% 0.053
G C C A A 0.052 6.5% 4.2% 0.22
A T C G A 0.040 1.1% 6.3% 0.0026a 0.17(0.05–
0.54)
G C C A G 0.033 3.9% 2.8% 0.50
A T C A A 0.025 1.2% 3.5% 0.091
G C T A G 0.016 2.2% 1.1% 0.32
A T C A G 0.015 0.3% 2.5% 0.034 0.12(0.02–
0.92)
A C T A A 0.010 2.0% 0.3% 0.062
aP = 0.012 after correcting the P-value for multiple testing by Haploview program using 10,000 permutations.
Table 5: CTLA-4 allele counts and frequencies in breast cancer patients and healthy controls
SNP Breast cancer (n = 117) Healthy controls (n = 148) P-value Odds ratio (95% 
CI)
Allele count 
(minor/major)
Allele frequency Allele count 
(minor/major)
Allele frequency
CTLA-4 -1661G/A# 49/169 22.5% 39/257 13.2% 0.0057 a 1.91 (1.21–3.02)
CTLA-4 -658T/C† 6/224 2.6% 40/250 13.8% 0.0000082 b 0.17 (0.08–0.37)
CTLA-4 -318T/C 33/201 14.1% 19/277 6.4% 0.0031 c 2.39 (1.34–4.27)
CTLA-4 +49G/A 79/155 33.8% 116/180 39.2% 0.20
CTLA-4 CT60G/A 95/139 40.6% 92/204 31.1% 0.023 1.52 (1.06–2.17)
# patients (n = 109), missing (n = 8); controls (n = 148), missing (n = 0)
† patients (n = 115), missing (n = 2); controls (n = 145), missing (n = 3)
aP = 0.031, bP = 0.00010 and cP = 0.017 after correcting the P-value for multiple testing by Haploview program using 10,000 permutations.BMC Cancer 2007, 7:173 http://www.biomedcentral.com/1471-2407/7/173
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up regulation of CTLA-4 expression, and may therefore
represent one mechanism that inhibits exaggerated
immune activity [21]. Although we did not obtain the TT
genotype of the -318 T/C site, our results show that T allele
frequency was associated with an increased risk of breast
cancer. Thus, our findings are consistent with earlier stud-
ies showing that the -318T allele increases the expression
of CTLA-4, inhibits the activation of T lymphocytes and
consequently limits the potency of tumor immunity. On
the other hand, our results did not show an association of
promoter genotypes and alleles with lymph node metas-
tasis and tumor size at the time of diagnosis in breast can-
cer patients.
Among all of the CTLA-4 gene variants, the +49 G/A pol-
ymorphism is the most extensively studied, since this is
the only polymorphism in the CTLA-4 gene that alters an
amino acid [7]. Moreover, the CTLA-4 +49G allele has
also been associated with incomplete glycosylation of the
signal peptide and altered processing in the endoplasmic
reticulum, which affects the CTLA-4-driven down regula-
tion of T-cell activation and is an important factor in the
pathogenesis of autoimmune diseases [16,22]. In our
study, there were no significant differences in genotype or
allele frequencies in +49 G/A between patients and
healthy controls. However, the tumor size was signifi-
cantly different between carriers of the AA and GG geno-
types at position +49 G/A in comparison to other
genotypes. This result suggests that +49 G/A was involved
in the progression of breast cancer rather than in its initial
development in Chinese Han women. The CT60 G/A pol-
ymorphism, located in 6.1-kb region 3' of the CTLA-4
gene, affects the ratio of trans-membrane to soluble
mRNA splice forms of the CTLA-4 gene. Furthermore, the
allele G is associated with lower levels of soluble CTLA-4
(sCTLA-4) expression. Genotypes producing higher levels
of sCTLA-4 have been shown to protect against the devel-
opment of autoimmune disease [23]. Many studies have
reported that the CT60G allele was increased in patients of
autoimmune diseases [24-26]. In our case-control study,
we report for the first time that the CT60G allele shows a
weak association with breast cancer, although the geno-
typic distributions were not significantly different
between patients and controls. Our findings were in con-
trast to previous hypotheses proposing that alleles confer-
ring susceptibility to autoimmunity are sparse in patients
with cancer. To substantiate this result, further case-con-
trol studies of other ethnic groups are required. In addi-
tion, more studies should be carried out to clarify the
exact mechanism of CT60 variant effects. In Taiwanese
and Dutch populations, the CTLA-4 CT60G allele is the
predominant one [24,27]. However, in our study, the
CT60A allele is more prevalent than the allele G, consist-
ent with previous reports [28]. Our study also revealed
there was no association of CT60 genotypes or alleles with
lymph node metastasis and tumor size at the time of diag-
nosis in breast cancer patients.
Previous studies have suggested that differences in CTLA-
4 function are most likely to be associated with the haplo-
type rather than with individual SNP [29]. The frequen-
cies of the haplotypes, ATCGA and ATCAG, were lower in
patients compared with healthy controls. However, after
the P-value was corrected for multiple testing only haplo-
type ATCGA showed a significant difference. This result
might imply a protective role for these two haplotypes in
combination of breast cancer in Chinese Han women.
Tsung-Hsien Su et al. reported that CGG (-318C, +49G,
CT60G) was the most prevalent haplotype in Taiwanese
women [30]. In this context, the most frequent haplotypes
in patients and controls were ACCAG and ACCGA. How-
ever, statistical analysis did not reveal significant differ-
ences in the frequencies of these two haplotypes between
patients and healthy controls. Furthermore, we found sig-
nificant association of ACCAA, ACCAG and ACCGA hap-
lotypes with tumor size, suggesting that these three
haplotypes participate in the progression of breast cancer.
Conclusion
Our data suggest that the CTLA-4 gene may be involved in
the susceptibility to and progression of breast cancer in
the Chinese Han population. The promoter region (-1661
G/A, -658 T/C, -318 T/C) of the CTLA-4 gene may be the
causal variants in breast cancer disease, whereas CTLA-4
+49 G/A may participate in the progression of breast can-
cer. In addition, this study also demonstrates that the
CTLA-4 haplotypes, ATCGA and ATCAG, may have a pro-
tective role in breast cancer. We also show that three hap-
lotypes, ACCAA, ACCAG and ACCGA, participate in the
progression of breast cancer. Considering that the limited
sample size may produce relative risk estimates lacking
adequate precision, extended analyses with larger sample
size should be carried out from different ethnic origins to
further verify this association.
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